Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vicore Pharma Holding AB ( (SE:VICO) ) has issued an announcement.
Vicore Pharma Holding AB announced that its drug, buloxibutid, has received Orphan Drug designation from Japan’s Ministry of Health, Labor and Welfare for treating idiopathic pulmonary fibrosis (IPF). This designation highlights the drug’s potential to address significant unmet medical needs in IPF, offering incentives like reduced fees and extended market exclusivity in Japan. The company has partnered with Nippon Shinyaku for development and commercialization in Japan, and the drug is currently being evaluated in a global Phase 2b trial, reinforcing Vicore’s position in the pharmaceutical industry.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a new class of drugs, particularly for respiratory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Their lead program involves buloxibutid, an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designations from the FDA and is under investigation in a global Phase 2b trial.
Average Trading Volume: 608,924
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.91B
Find detailed analytics on VICO stock on TipRanks’ Stock Analysis page.